Key Segments:
By Phase
-
Phase I
-
Phase II
-
Phase III
-
Phase IV
By Study Design
-
Interventional
-
Observational
-
Expanded Access
By Indication
-
Type 1 Diabetes Mellitus
-
Type 2 Diabetes Mellitus
-
Gestational Diabetes
-
Prediabetes
By Service
-
Laboratory Services
-
Clinical Trial Management and Monitoring
-
Data Management and Biostatistics
-
Regulatory and Medical Writing
-
Other Services
By Sponsor
-
Pharmaceutical and Biopharmaceutical Companies
-
Contract Research Organizations
-
Academic and Government Institutes
-
Other Sponsors
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include IQVIA, ICON, Labcorp Drug Development, Parexel, Syneos Health, Fortrea, Medpace, WuXi Clinical Development, and Celerion, among others.
Key opportunities include disease-modifying Type 1 diabetes therapies, expanding continuous glucose monitoring endpoint adoption, and growing connected site-network models shortening study start-up timelines.
The market is driven by an unusually deep late-stage pipeline of glucose-lowering and weight-management candidates, rising global Type 2 diabetes prevalence, and growing demand for comparative cardiometabolic outcome evidence.
The Type 2 Diabetes Mellitus segment dominated the Diabetes Clinical Trials Market, accounting for approximately 61.30% share in 2025.
The North America region dominated the Diabetes Clinical Trials Market in 2025 with approximately 48.60% revenue share.
